Collaborative Efforts and Reports. (a) The parties agree that the successful execution of the R&D Program will require the collaborative use of both parties' areas of expertise. The parties shall keep the RDSC fully informed about the status of the portions of the R&D Program they respectively perform. Without limiting the foregoing, each party shall furnish to the RDSC quarterly written reports within 30 days after the end of each quarterly period, describing the progress of its activities in connection with the R&D Program in reasonable detail, including: (i) a detailed accounting of the FTEs used, (ii) a reasonably detailed synopsis of the screening and testing of Gene Variants and Shuffled Genes, and the development of Shuffled Genes and PIONEER Licensed Products, and (iii) a description of Intellectual Property arising from the R&D Program. It is understood and agreed that reports regarding the development and commercialization of PIONEER Licensed Products outside the scope of the R&D Program shall be subject to (P)5.3 below, and that reports regarding the development and commercialization of MAXYGEN Licensed Products outside the scope of the R&D Program shall be subject to (P)5.4 below.
(b) MAXYGEN and PIONEER shall cooperate in the performance of the R&D Program and, subject to any confidentiality obligations to third parties, shall exchange information and materials as necessary to carry out the R&D Program, pursuant to the provisions of this Agreement. Each party will attempt to accommodate any reasonable request of the other party to send or receive personnel for purposes of discussing the R&D Program. Such visits and access will be at agreed times, have defined purposes, be of agreed limited duration and be scheduled in advance. The requesting party will bear the travel and lodging costs of any such personnel. It is understood that any such visiting personnel may be subject to reasonable restrictions to protect intellectual property outside the R&D Program and the rights of third parties, which may include sequestration from research projects outside of the R&D Program.
(c) During the Research Program and for a period of three (3) years thereafter, MAXYGEN and PIONEER shall maintain records of the R&D Program (or cause such records to be maintained) in sufficient detail and good scientific manner as will properly reflect all work done in the R&D Program and results achieved in the performance of the R&D Program; provided, that laboratory notebooks relating to activities conducted...
Collaborative Efforts and Reports. (a) The Parties agree that the successful execution of the R&D Program will require the collaborative use of both Parties' areas of expertise. The Parties shall keep the RMC fully informed about the status of the portions of the R&D Program they respectively perform. Without limiting the foregoing, each Party shall furnish to the RMC [*****] reports within [*****] days after the end of each [*****] period, describing the progress of its activities in connection with the R&D Program in reasonable 8 * Confidential Treatment Requested detail, including at least:
(i) an estimation by DIVERSA of the FTEs used for each Research [*****] and Research [*****] and the budget used for each [*****] Plan, and
(ii) a summary of the testing and development of [*****] Enzymes and Licensed [*****].
(a) shall describe all [*****] Enzymes that have been put into [*****], and shall also contain sufficient other information to allow a Party to monitor the other Party's compliance with this Agreement, including without limitation, each Party's obligations with respect to the accomplishment of the [*****]. All reports and information provided under this Section 2.1.2 (a) shall be deemed Confidential Information of the Party which provided the information.
(b) DIVERSA and DOW shall cooperate in the performance of the R&D Program and, subject to any confidentiality obligations to Third Parties or legal restrictions, shall exchange information [*****] as necessary to carry out the R&D Program pursuant to the provisions of this Agreement. Each Party will attempt to accommodate any reasonable request of the other Party to send or receive personnel for purposes of discussing the R&D Program. Such visits and access will be at mutually agreed times, have defined purposes, be of agreed limited duration, and be scheduled in advance. Each Party shall [*****] of their respective personnel related to these visits. It is understood that any such visiting personnel may be [*****] the R&D Program and the rights of Third Parties, which may include [*****] of the R&D Program. All personnel shall abide by the required rules for any Third Party visiting that Party's site, including, but not limited to, [*****] and other matters.
(c) During the Research Term and for a period of [*****] years thereafter, DIVERSA and DOW shall maintain records of the R&D Program (or cause such records to be maintained) in sufficient detail and good scientific manner as will properly reflect all work done in the R&D Pr...
Collaborative Efforts and Reports. (a) The Parties agree that the successful execution of the Research Program will require the collaborative use of both Parties' areas of expertise. Each Party shall keep the RC fully informed about the status of the portions of the Research Program they respectively perform including, without limitation, summaries of their direct uses of the Project Data itself for so long as GENENTECH shall have an option to license such Project Data hereunder. CURAGEN shall promptly provide GENENTECH with a description of Project Data Sets from completed Research Projects. All information provided hereunder will be treated as Confidential Information of the disclosing Party pursuant to the provisions of Article 4.
(b) Scientists at CURAGEN and GENENTECH shall cooperate in the performance of the Research Program and, subject to any confidentiality obligations to third parties, shall exchange information and materials as necessary to carry out the Research Program, subject to the provisions of Section 4. Each Party will attempt
Collaborative Efforts and Reports. The Parties agree that the successful execution of the Research Program will require the collaborative use of both Parties’ areas of expertise. The Parties shall keep the JDC and each other fully informed about the status of the Research Program. Scientists at ImmunoGen and Bayer shall cooperate in the performance of the Research Program and, subject to any confidentiality obligations to Third Parties, shall exchange information and materials in a mutually acceptable secure manner as necessary to carry out the Research Program, subject to the provisions of Section 6 hereof.
Collaborative Efforts and Reports. (a) The Parties agree that the successful execution of the Research Program will require the collaborative use of both Parties' areas of expertise. The Parties shall keep the RC fully informed about the status of the portions of the Research Program they respectively perform. In particular, without limitation, each Party shall furnish to the RC quarterly written reports within thirty (30) days after the end of each quarterly period, describing the progress of its activities in reasonable detail, including (x) a summary of Project Data from ongoing Research Projects, (y) a summary of uses of Project Data and (z) a description of Project Data Sets from [Confidential Treatment Requested]
(b) Scientists at CURAGEN and BIOGEN shall cooperate in the performance of the Research Program and, subject to any confidentiality obligations to third parties, shall exchange information and materials (including BIOGEN Proprietary Material) as necessary to carry out the Research Program, subject to the provisions of Section 4. Each Party will attempt to accommodate any reasonable request of the other Party to send or receive personnel for purposes of collaborating or exchanging information under the Research Program. Such visits and/or access will have defined purposes and be scheduled in advance. The requesting Party will bear the reasonable travel and lodging costs of any such personnel.
(c) CURAGEN will give written notice to BIOGEN and the RC upon completion of the Project Data Set from each Research Project. "Completion" of a Project Data Set shall occur upon generation of all QEA/GeneCalling data or MIM/PathCalling data from a Research Project as contemplated by the Research Plan.
Collaborative Efforts and Reports. The parties agree that the successful execution of the Alliance Program will require the collaborative use of both parties' areas of expertise. The parties shall keep the Alliance Steering Committee fully informed about the status of the portions of the Alliance Program they respectively perform separately and/or jointly. Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company's application requesting confidential treatment under Rule 406 of the Securities Act.
Collaborative Efforts and Reports. The Parties agree that the successful execution of the Research Program will require the collaborative use of both Parties’ areas of expertise. The Parties shall keep the Collaboration Committee and each other fully informed about the status of the Research Program. Scientists at ImmunoGen and Biogen Idec shall cooperate in the performance of the Research Program and, subject to any confidentiality obligations to Third Parties, shall exchange information and materials in a mutually acceptable secure manner as necessary to carry out the Research Program, but subject to the provisions of Section 6 hereof. The Parties expect that such exchange of information and materials may involve short-term on-site visits (up to a few weeks) by scientists of each Party to the facilities of the other Party.
Collaborative Efforts and Reports. The parties agree that the successful execution of the R & D Program will require the collaborative use of both parties' areas of expertise. The parties shall keep the JSC and each other fully informed about the status of the portions of the R & D Program they respectively perform. In particular, without limitation, each party shall furnish to the JSC and each other a quarterly written report, describing the progress of its activities in reasonable detail, no later than thirty (30) days after the end of each Fiscal Quarter. Scientists at CHEMGENICS and WYETH-AYERST shall cooperate in the performance of the R & D Program and, subject to any confidentiality obligations to third parties, shall exchange information and materials as necessary to carry out the R & D Program, but subject to the provisions of Sections 4 and 5 hereof. Each party will attempt to accommodate any reasonable request of the other party to send or receive personnel for purposes of collaborating or exchanging information under the R & D Program. Such visits and/or access will have defined purposes and be scheduled in advance. The requesting party will bear the travel and lodging costs of any such personnel.
Collaborative Efforts and Reports. The parties agree that the successful execution of the R & D Program will require the collaborative use of both parties' areas of expertise. The parties shall keep each other fully informed about the status of the portions of the R & D Program they respectively perform. Designated representatives of SIGA and WYETH-AYERST shall cooperate in the performance of the R & D Program and, subject to any confidentiality obligations to third parties, shall exchange information and materials as necessary to carry out the R & D Program, but subject to the provisions of Sections 4 and 5 hereof. Each party will attempt to accommodate any reasonable request of the other party to send or receive personnel for purposes of collaborating or exchanging information under the R & D Program. Such visits and/or access will have defined purposes and be scheduled in advance. Each party will bear its relevant travel and lodging costs.
Collaborative Efforts and Reports. The parties agree that the successful execution of the R&D Program will require the collaborative use of both parties’ areas of expertise. The parties shall keep the RSC fully informed about the status of the portions of the R&D Program they respectively perform. In particular, without limitation, SEMBIOSYS shall furnish to the RSC quarterly written reports within thirty (30) days after the end of each Calendar Quarter, describing the progress of its activities in reasonable detail, including a description of Program Intellectual Property arising from SEMBIOSYS’ research efforts and accomplishments.
